Case sharing: Application of artificial intelligence in drug discovery
- Case sharing: AI technology is applied in drug discovery’s multiple stages
Drug discovery stage:
efficiently screen therapeutic targets and design drugs，saving the costs of drug discovery and
shortening the time required for drug discovery
Pre-clinical development stage:
deal with the problems of molecular characteristics, water solubility, toxicity, oral absorption
potential and other issues of the drug
Clinical research stage:
analyze issues about drug redirection, patient recruitment, optimization of clinical trials, etc.
Approval and on-market stage:
new drug research and development intelligence analysis and post-marketing safety evaluation, etc.
- Limitations of the AI technology in drug discovery
- Guest speaker:research spotlight on an Australian biotech company innovation breakthrough
Event details
|
DATE Wednesday Nov 24th, 2021 VENUE Online Webex / Zoom TIME 10:00 – 11:00 Berlin time (CET) 16:00 - 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Nov 23rd, 2021 |
PRESENTERS Lingling Cao, CEO & Founder Dr Han Wen, R&D Scientist, DeepSense Technology Dr Glenn Gilbert, Guest speaker REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 10:00 - 10:30 |
– Case sharing: Artificial intelligence technology is applied in drug discovery’s multiple stages – Limitations of the AI technology in drug discovery |
by Dr Han Wen (Chinese) |
| CET 10:30 - 10:35 | Linkedbio services & projects introductions | by Lingling Cao (English) |
| CET 10:35 - 10:55 | Guest speaker:research spotlight on an Australian biotech company innovation breakthrough | by Dr Glenn Gilbert (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Dr Han Wen R&D Director, Beijing DP Technology Dr. Wen received his PhD in Physics from the State University of New York at Buffalo, USA, followed by a postdoctoral fellowship at the CCBR, University of Toronto. He has extensive research experience in molecular dynamics simulation, membrane proteins and deep learning-driven macromolecular drug design, with results published in top journals such as PNAS and JMC. He is currently a full-time scienentist at Beijing DP Technology, responsible for ion channel realated research and macromolecular drug design. |
 |
Dr Glenn Gilbert Rhythm Biosciences Ltd A pragmatic and commercial driven leader with over 17 years of experience in the healthcare sector (incl. pharmaceutical, medical device (Rx and OTC) and IVD industry) across domestic and international markets. His expertise spans strategy, manufacturing and sales, with a sharp focus on disciplined execution through culture, relationships and planning. Glenn has held leadership roles at Seqirus, a CSL company (ASX:CSL), and recently at Medical Developments International (ASX:MVP) with extensive business experience across the UK, Europe, Asia, North and South America. He specialises in mergers and acquisitions, corporate development, operations, intellectual property and legal portfolios |
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |